METACIR: METAbolic Control of the Immune Response

  • Research type

    Research Study

  • Full title

    Investigating the metabolic control of immune responses in health and in autoimmune diseases; identification of new immune regulatory pathways with therapeutic potential.

  • IRAS ID

    155723

  • Contact name

    Andrew P Cope

  • Contact email

    andrew.cope@kcl.ac.uk

  • Sponsor organisation

    King's College London

  • Duration of Study in the UK

    3 years, 11 months, 28 days

  • Research summary

    Upon infection, the human body reacts by activating the immune system. Cells of the immune system will activate and mount a response against the pathogen until it has been cleared from the body. Once this has been achieved, the response will shut down and return to a basal situation, ready for the next challenge. However, in some individuals, the immune response is not shut down appropriately and this might lead to a situation where the cells are activated in a chronic manner and may attack their own tissues (this is called an autoimmune reaction). The destruction of the body tissues may lead to the development of an autoimmune disease such as Rheumatoid Arthritis (RA). Despite advances in the knowledge on how the immune response is activated and regulated, the exact mechanism by which this is happening is not fully understood, neither are the differences between healthy and diseased individuals. Our group has described several novel abnormalities in the activation and regulation of the immune cells in autoimmune disease. This study is aimed at dissecting the mechanisms that drive those abnormalities. We will obtain samples from blood and sometimes from inflamed sites such as the synovial fluid from patients with chronic inflammatory diseases such as RA. We will isolate the immune cells and perform extensive laboratory analyses to compare the behavior of cells from healthy and diseased individuals. The results that we will obtain will improve the current understanding of alterations in immune responses in disease and could lead to a better therapy.

  • REC name

    London - Bloomsbury Research Ethics Committee

  • REC reference

    18/LO/0399

  • Date of REC Opinion

    18 Apr 2018

  • REC opinion

    Further Information Favourable Opinion